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IntroductIon 
Systemic lupus erythematosus (SLE) is an autoimmune
disorder that may affect multiple organs and systems1,
including cutaneous involvement2. Skin manifestations
are frequent in adult and juvenile SLE (JSLE) patients,
and are the first symptoms of the disease in 23% to 28%
of patients2.
A variety of cutaneous features can be evidenced in
lupus patients, including lupus erythematosus panni-
culitis (LEP) or lupus erythematosus profundus3,4. LEP
is a rare form of chronic cutaneous lupus erythemato-
sus (CCLE) and it is characterized by recurrent nodu -
les or plaques in deep dermis and subcutaneous tis-
sues, mainly affecting the proximal limbs, buttocks and
face, leading to local swelling and skin atrophy. Of note,
the prevalence of this manifestation in paediatric lupus
population was not reported.  
Therefore, we reviewed our data from January 1983
to December 2010 that included the 5,508 patients of
Paediatric Rheumatology Unit of the Ins tituto da Cri-
ança da Faculdade de Medicina da Universidade de São
Paulo. We identified 278 (5%) ca ses that met the
Ameri can College of Rheumatology (ACR)5 classifica-
tion criteria for JSLE. Two (0.7%) of them had JSLE and
were described herein. This study was approved by the
Local Ethics Committee of our University Hospital.
cAse reports
cAse 1
An 8-year old boy was admitted in our University Hos-
pital with one-year history of fever and recurrent ten-
der erythematosus nodules, with skin hyperpigmenta-
tion and atrophy affecting the face, proximal upper
limbs, back and trunk. At that time, laboratory exams
revealed hemoglobin 14g/dL, hematocrit 38.6%, white
blood cell count 9,700/ /mm³ (60% neutrophils, 35%
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them met the American College of Rheumatology clas-
sification criteria for JSLE. Two (0.7%) of them had LEP
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flammatory subcutaneous nodules or plaques at the
time of diagnosis, and the histopathologic pattern evi-
denced lobular or mixed panniculitis with lymphocy -
tic inflammatory cells of the fat lobule. Treatments for
LEP inclu ded mainly antimalarials, systemic corticos-
teroids and sunscreen protection. One male patient re-
quired thalidomide and immunosuppressive drugs, in-
cluding mycophenolate mofetil, cyclosporin and intra-
venous cyclophosphamide. However, skin lesions im-
proved only after rituxi mab treatment. 
Discussion: LEP was rarely observed in our cohort of
JSLE patients as the first lupus manifestation. Anti-
-CD20 monoclonal antibody therapy may be an option
for refractory LEP treatment in children.
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lymphocytes, 2% eosinophils and 3% monocytes),
platelets 216,000/ /mm³, urinalysis (1,000 leukocytes
and zero erythrocytes), C3 184 mg/dL (normal 90-
-180), C4 22 mg/dL (normal 10-44), IgG 2000 mg/dL
(normal 570-1320), IgA 306 mg/dL (normal 65-240),
IgM 149 mg/dL (normal 60-175), erythrocyte sedi-
mentation rate (ESR) 45 mm 1st hour (normal < 20), 
C-reac tive protein (CRP) 2.75 mg/L (normal < 5) and
proteinuria 0.22 g/24h. Immunological tests were
posi tive for antinuclear antibodies (ANA) 1:80 (fine
speckled pattern) and negative for other serum anti-
bodies: anti-double stranded DNA (anti-dsDNA), anti-
-Sm, anti-RNP, anti-Ro, anti-La, anti-Jo-1, anti-Scl-70,
antineutrophil cytoplasmic antibody (ANCA), and IgG
and IgM anticardiolipin. Skin biopsy from upper back
region showed septal and lobular panniculitis, with
inflammatory infiltrate predominantly composed of
lymphocytes in fat lobules and paraseptal regions, hya-
line fat necrosis, without vasculitis. Dermoepidermal
changes evidenced loss of the normal organization and
orientation of basal cells, basement membrane thicke -
ning, and superficial and deep perivascular dermal
lymphocytic infiltrates. Direct immunofluorescence
study of lesional skin was negative to IgG, IgM, IgA
and C3. Diagnosis of LEP was established and the pa-
tient was treated with prednisone (2 mg/kg/day, pro-
gressively tapered to 20 mg/day), chloroquine diphos-
phate (5 mg/kg/ /day), cyclosporine (3 mg/kg/day) and
sunscreen protection, with improvement of all clinical
ma ni festations. At 9 years of age, he presented hea da -
che and seizures. Brain magnetic resonance imaging
showed high signal intensity on T2-weighted ima ges
predominantly in the posterior regions compatible
with reversible posterior leukoence pha lopathy, and cy-
closporine was replaced by azathioprine (100 mg/day).
One year later, he develo ped recurrent erythematosus
nodules with hy perpigmentation on the face, neck,
arms, back, trunk and inferior limbs. Mycophenolate
mofetil (30 mg/kg/day) and thalidomide (2 mg/kg/day)
were started. At 11 years, he presented severe ischemia
and loss of distal segment of the second finger of right
hand and generalized skin vasculitis, diffuse tender
erythematosus nodules (Figure 1), affecting face, arms,
shoulders, trunk, hands, legs and feet and pericarditis.
At that moment, his exams showed: white blood cell
count 1,900/mm³ (54% neutrophils, 39% lympho-
cytes, 6% monocytes  and 1% eosinophils), platelets
108,000/mm³, proteinuria 0.7 g/24h, ANA 1:160 (fine
speckled pattern), anti-Ro 1:40 UI/mL and the diag-
nosis of JSLE was confirmed according to the ACR cri-
teria5. The Systemic Lupus Erythematosus Disease Ac-
tivity Index 2000 (SLEDAI-2K) score was 136. He was
treated with monthly intravenous cyclophosphamide
(750 mg/m2/dose) and three pulses of intravenous
methylprednisolone on a monthly basis for four con-
secutive months. However, after four months, he de-
veloped diffuse tender erythematosus nodules, palpa-
ble purpura, skin ulcers, and ischemia of distal seg-
ment of the third finger of left hand. A treatment with
four weekly doses of rituxi mab (375 mg/m2 per dose)
showed a remarkable improvement of the skin vas-
culitis, despite the persistence of both diffuse skin hy-
perpigmentation and atrophy. No adverse events were
observed after anti-CD20 monoclonal antibody thera -
py. The patient has remained symptom free for over
12 months.  
cAse 2
A 13-year old girl presented with a history of fever,
polyarthritis in shoulders, left elbow, knees and an-
kles, and cervical lymphadenopathy for the last 20
days. Two subcutaneous, erythematosus and tender
nodules were evidenced on the left leg. The patient
was hospitalized in our University Hospital and labo-
ratory exams revealed hemoglobin 10.5g/dL, hemato -
crit 31.2%, white blood cell count 1,500/mm³ (40%
neutrophils, 43% lymphocytes, 7% eosinophils and
10% monocytes), platelets 202,000/mm³, C3 0.88 g/L
(normal 0.5-1.8), C4 0.08 g/L (normal 0.1-0.4), uri-
nalysis (2,000 leukocytes, zero erythrocyte), protei-
 nu ria 0.7 g/day, ESR 57 mm 1st hour and CRP 162
Figure 1. Skin vasculitis and diffuse tender erythematosus
nodules in right hand with loss of distal segment of the second
finger in an 11-year old boy patient with lupus erythematosus
panniculitis.
ÓRgÃO OFICIAL DA SOCIEDADE PORTUgUESA DE REUMATOLOgIA
84
lupus panniculitis in childRen
mg/L. Immunologic tests revealed ANA titers of 1:160
(homogeneous pattern), positive anti-dsDNA, anti-
-thyroid peroxidase, anti-thyroglobulin, anticardio -
lipin IgG (67.3 GPL) and IgM anticardiolipin (15.4
MPL) antibo dies. Serologic tests for hepatitis virus A,
B and C, Epstein-Barr virus, parvovirus B19, cytome -
galo vi rus, toxoplasmosis and human immunodefi-
ciency virus (HIV) infections were negative. Bone mar-
row aspirate was normal. After five days of hospitali -
zation, the other serum autoantibodies were negative:
anti-Sm, anti-RNP, anti-Ro and anti-La. The skin biop-
sy from left leg showed lobular panniculitis with in-
flammatory infiltrate composed of lymphocytes and
lymphocytic vasculitis in the small-sized vessels. No
deposits of IgG, IgM and C3 were observed in direct
immunofluorescence of lesional skin. Therefore, the
diagnosis of JSLE5 and LEP were established. At that
moment, the SLEDAI-2K score was 206. At the same
day of lupus diagnosis, she had sepsis despite previous
ceftriaxone use, and died after 12 days of hospitaliza-
tion. The autopsy showed acute tubular necrosis, dif-
fuse alveolar damage compatible with acute respirato-
ry distress syndrome, and diffuse cerebral edema, cere-
bellar infarcts and brain herniation with multiple he -
morrhages compatible with sepsis.
dIscussIon
To our knowledge, this is the first study that eva luated
the prevalence of LEP in a large population of Paedia -
tric Rheumatology University Hospital, showing a rare
frequency of this type of skin involvement as the first
disease manifestation. 
Of note, LEP is a rare chronic lupus cutaneous in-
volvement, and was reported in adult SLE and discoid
lupus, as a single skin abnormality (with and without
systemic manifestations)7-11, and was rarely described
in JSLE population11. Indeed, the prevalence of LEP
associated with SLE ranged from 2% to 5%, and this
alteration may occur before or after the disease onset7.
Contrary to other subtypes of cutaneous lupus, these
lesions occur frequen tly in female gender8,10,11. 
Usually, LEP manifests as tender deep subcutaneous
nodules or plaques that involve shoulders, upper arms,
trunk, buttocks, and legs7,11, as obser ved herein. In-
terestingly, a predilection for facial involvement was
evidenced in pediatric cases7, regardless of the absence
of clinical and histopathologic signs of discoid lupus
on the overlying skin, as shown in our two JSLE ca ses.
In our series, other initial clinical manifestations in LEP
patients included fever and pericarditis8,11. 
Although there are no specific serologic findings in
LEP, some studies suggest a high probabili ty of sys-
temic involvement in patients with LEP and ANA12.
Of note, one of our cases had reversible posterior
leukoencephalopathy possibly associated with cy-
closporine treatment. This is a neurologic abnor mality
characterized by headache and seizure. The imaging
study confirms the diagnosis, sho w ing posterior leu-
coencephalopathy, which was rarely reported in JSLE
patients13. 
Histopathologic pattern in LEP patients is cha rac -
terized by lobular or mixed panniculitis with lympho-
cytic inflammatory cells of the fat lobu le9,10,14. Other
characteristics include dermoepidermal changes and
lymphocytic vasculitis in the small vessels of the fat lo -
bu le, as described in our cases. Importantly, differen-
tial diagnosis encompass subcu taneous panniculitis-
-like T-cell lymphoma, deep morphea, erythema nodo -
sum, erythema induratum of Bazin, post-steroid pan-
niculitis7-8, Weber-Christian disease and sarcoidosis.
Treatments of LEP include mainly antimalarials,
which is the first therapy option10,11, mainly in non-
-smokers patients7. Corticosteroids are the second line
of therapy, although severe adverse events may be ob-
served7,11.Topical corticosteroids are general ly ineffec-
tive, and the intralesional administration can lead to lo-
cal atrophy and ulcerations10. The depth and exten-
sion of the lesion suggest that the ultraviolet light may
participate in the disease’s pathogenesis. Therefore the
use of sunscreen protection is indicated, as it was in our
patients10.
Other treatment modalities for refractory cases have
included thalidomide7,10, and immunosuppressive
drugs, such as methotrexate14, mycophenolate
mofetil10 cyclosporin and intravenous cyclophospah-
mide7, as used in our first case. Rituxi mab was the only
therapy to induce skin impro vement in one of our pa-
tients, as previously des cribed in one adult with lupus
panniculitis15. To our knowledge, this was the first case
reported with LEP and JSLE that was treated with anti-
-CD20 monoclonal antibody therapy. In addition, one
of our patients, who had acute and severe lupus, had
severe sepsis, even before receiving lupus treatment.
In conclusion, LEP proved to be rare in our pediatric
population with lupus and it may be the first lupus
manifestation. Anti-CD20 monoclonal antibody thera -
py may be an option for refractory LEP treatment in
children.
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